Stockreport

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 [Yahoo! Finance]

Cabaletta Bio, Inc.  (CABA) 
PDF – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free clinic [Read more]